EE+ POEM Archive
The risk of clinically relevant bleeding is lower with apixaban than with rivaroxaban for symptomatic acute VTE
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "The Risk of Clinically Relevant Bleeding Is Lower With Apixaban Than With Rivaroxaban for Symptomatic Acute VTE." EE+ POEM Archive, John Wiley & Sons, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377638/all/The_risk_of_clinically_relevant_bleeding_is_lower_with_apixaban_than_with_rivaroxaban_for_symptomatic_acute_VTE.
The risk of clinically relevant bleeding is lower with apixaban than with rivaroxaban for symptomatic acute VTE. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2026. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377638/all/The_risk_of_clinically_relevant_bleeding_is_lower_with_apixaban_than_with_rivaroxaban_for_symptomatic_acute_VTE. Accessed May 19, 2026.
The risk of clinically relevant bleeding is lower with apixaban than with rivaroxaban for symptomatic acute VTE. (2026). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377638/all/The_risk_of_clinically_relevant_bleeding_is_lower_with_apixaban_than_with_rivaroxaban_for_symptomatic_acute_VTE
The Risk of Clinically Relevant Bleeding Is Lower With Apixaban Than With Rivaroxaban for Symptomatic Acute VTE [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2026. [cited 2026 May 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377638/all/The_risk_of_clinically_relevant_bleeding_is_lower_with_apixaban_than_with_rivaroxaban_for_symptomatic_acute_VTE.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - The risk of clinically relevant bleeding is lower with apixaban than with rivaroxaban for symptomatic acute VTE
ID - 3377638
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377638/all/The_risk_of_clinically_relevant_bleeding_is_lower_with_apixaban_than_with_rivaroxaban_for_symptomatic_acute_VTE
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
